natural glp 1 agonist GLP-1 receptor agonists and next-generation metabolic hormone therapies in chronic kidney disease Understanding GLP-1 Agonists

These efforts have led to the development of various GLP-1 receptor agonists, the most recent being semaglutide and tirzepatide, approved for the treatment of type 2 diabetes in 2018 and 2022, respectively

Over the past decade, four landmark cardiovascular outcome trials have quietly rewritten how we think about cardiometabolic risk: LEADER (2016) Liraglutide cut MACE by 13%, CV death by 22%, and all-cause mortality by 15% in high-risk T2DM patients

Weve broken down the benefits, costs, and the difference between brand-name and compounded options so you can find an affordable GLP-1 weight loss opportunity without insurance

The gut knows you are eating and tells the pancreas to get ready to pack away the extra calories as fat

J Diabetes Complications (2014) 28:38692

CVOTs cardiovascular outcome trials, T2DM type 2 diabetes mellitus, CVD cardiovascular disease, HF heart failure, CKD chronic kidney disease, HbA1c glycated hemoglobin, eGFR estimated glomerular filtration rate, PCI percutaneous coronary intervention, CABG coronary artery bypass graft, GLP-1R GLP-1 receptor, T1DM type 1 diabetes mellitus, GLP-1RAs glucagon-like peptide-1 receptor agonists, DPP-4i DPP-4 inhibitor, HR hazard ratio, CI confidence interval Except for ELIXA and EXSCEL [56, 59], all other major CVOTs point towards cardiovascular benefits of GLP-1RAs [53, 54, 61, 63, 6668]